Synapse Biomedical Inc (SBI) is a company founded in September 2002 by Anthony Ignagni to commercialize the NeuRx Diaphragm Pacing System (DPS). The electrical stimulation system was developed over a twenty-year period at Case Western Reserve University and the University Hospitals of Cleveland for the treatment of chronic respiratory insufficiency. The innovative system allows technology to meet clinical needs in spinal cord injuries, diaphragm conditioning in muscular dystrophies (such as ALS) and respiratory short-term intensive care settings.
In September 2011 Synapse Biomedical announced that the U.S. Food and Drug Administration (FDA) approved its NeuRx DPS for treating amyotrophic lateral sclerosis (ALS) patients who have stimulatable diaphragms and are experiencing chronic hypoventilation.
The company has partnered with treatment centers in 24 countries that have skilled Board Certified Laparoscopic Surgeons qualified to perform the NeuRx DPS® implantation procedure.
Anthony R. Ignagni
President, CEO & Co-Founder
Vice President of Quality
Chief Operating Officer & Managing Director-Europe
V.P. of Product Development & Operations
Documentaries, videos and podcasts
- Cluster: COVID-19A cluster of topics related to COVID-19. COVID-19 is the abbreviated name for coronavirus disease 2019, a respiratory disease caused by a novel coronavirus strain called SARS-CoV-2. COVID-19 was first detected in Wuhan City, China and the outbreak was declared a pandemic on March 11, 2020 by the WHO.